High Expression of TGF-β1 Contributes to Hepatocellular Carcinoma Prognosis via Regulating Tumor Immunity

Background: Transforming growth factor-beta (TGF-beta) signaling is essential in initialization and progression of hepatocellular carcinoma (HCC). Therefore, a treatment targeting TGF-beta pathway may be a promising option for HCC control. Methods: First, publicly available RNA-seq datasets and clinical characteristics of 374 HCC patients in The Cancer Genome Atlas (TCGA) database were downloaded. Then, Cox regression analysis and LASSO analysis were used to construct a prognostic model for TGF-beta family genes. The area under the curve (AUC) of the risk signature was calculated to evaluate the predictive power of the model. Cox regression analysis was applied to predict whether TGF-beta 1 can be an independent prognosis factor for HCC. Next, hazard ratio and survival analyses were performed to investigate the correlation between TGF-beta 1 expression and survival time. Furthermore, differential expression level of TGF-beta 1 in HCC tissues and cells was determined. In addition, Gene Set Enrichment Analysis (GSEA) identified the top significantly activated and inhibited signal pathways related to high expression of TGF-beta 1. Finally, the CIBERSORT tool was adopted to correlate the tumor-infiltrating immune cells (TICs) with TGF-beta 1 expression in HCC cohorts. Results: Cox regression analysis and LASSO analysis revealed that seven TGF-beta family members (including TGF-beta 1) could be used as prognostic factors for HCC. Interestingly, TGF-beta 1 was demonstrated to be an independent prognostic factor of HCC. RT-qPCR and immunofluorescence staining confirmed the high expression of TGF-beta 1 in HCC cell lines and tissues, which is significantly related to pathological classifications, poor prognosis, and short survival time. Finally, GSEA and CIBERSORT analyses suggested that TGF-beta 1 may interact with various immune cells and influence the prognosis of HCC patients through Tregs and gamma delta T cells. Conclusion: We established a novel prognostic prediction method to predict the risk scores of TGF-beta genes in HCC prognosis. TGF-beta 1 is highly expressed in HCC cell lines and tissues, correlates to poor prognosis, and thus can be used as a potential biomarker to predict HCC prognosis. We showed that TGF-beta 1 may play its roles in HCC prognosis by modulating the immune microenvironment of tumor cells. Our data may shed more light on better understanding the role of TGF-beta 1 in HCC prognosis.

Automated summary

Analysis of RNA-seq data and clinical characteristics revealed that seven TGF-beta family members (including TGF-beta 1) could serve as prognostic factors for HCC. High expression of TGF-beta 1 in HCC cell lines and tissues was associated with pathological classifications, poor prognosis, and short survival time.